New advances in models and strategies for developing anti-obesity drugs

Bibliography

• Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol 2012;9(1):13-27
   PubMed Web of Science ®Google Scholar
• Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011;378(9793):815-25
   PubMed Web of Science ®Google Scholar
• Wang Y, Beydoun MA, Liang L, et al. Will all Americans become overweight or obese? Estimating the progression and cost of the us obesity epidemic. Obesity (Silver Spring) 2008;16(10):2323-30
   PubMed Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States. 2009-2010. NCHS Data Brief 2012;82:1-8
   PubMedGoogle Scholar
• Kopelman PG. Obesity as a medical problem. Nature 2000;404(6778):635-43
   PubMed Web of Science ®Google Scholar
• Eisenmann JC, Katzmarzyk PT, Perusse L, et al. Aerobic fitness, body mass index, and CVD risk factors among adolescents: the Quebec family study. Int J Obes 2005;29(9):1077-83
   Web of Science ®Google Scholar
• Batty GD, Shipley MJ, Jarrett RJ, et al. Obesity and overweight in relation to organ-specific cancer mortality in London (UK): findings from the original Whitehall study. Int J Obes 2005;29(10):1267-74
   Web of Science ®Google Scholar
• CDC: Economics consequences of overweight and obesity: CDC. 2011. Available from: http://www.cdc.gov/obesity/causes/economics.html
   Google Scholar
• Hainer V, Hainerova IA. Do we need anti-obesity drugs? Diabetes/metabolism research and reviews. 2012;28(Suppl 2):8-20
   Google Scholar
• FDA: Guidance for industry developing products for weight management. 2007. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071612.pdf
   Google Scholar
• Bhasin S, Wallace W, Lawrence JB, Lesch M. Sudden death associated with thyroid hormone abuse. Am J Med 1981;71(5):887-90
   PubMed Web of Science ®Google Scholar
• Chemistry COPA. Dinitrophenol not acceptable for n.N.R. JAMA 1935;105:31-3
   Google Scholar
• Asher WL. Mortality rate in patients receiving ‘diet pills'. Curr Ther Res Clin Exp 1972;14(8):525-39
   PubMed Web of Science ®Google Scholar
• Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa 1985;27(2-3):160-71
   PubMedGoogle Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337(9):581-8
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):1826-32
   PubMed Web of Science ®Google Scholar
• Larsson TA, Olsson F, Sundstrom G, et al. Pufferfish and zebrafish have five distinct NPY receptor subtypes, but have lost appetite receptors Y1 and Y5. Ann N Y Acad Sci 2005;1040:375-7
   PubMed Web of Science ®Google Scholar
• Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343(25):1833-8
   PubMed Web of Science ®Google Scholar
• Weir MA, Beyea MM, Gomes T, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011;171(7):703-4
   PubMed Web of Science ®Google Scholar
• Who: obesity and overweight: Key facts. 2011. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html
   Google Scholar
• Prolor Biotech reports positive preclinical results in weight loss study of its long-acting anti-obesity drug candidate. 2011. Available from: http://www.prolor-biotech.com/?CategoryID=211&ArticleID=99&sng=1
   Google Scholar
• Schaeffer M, Langlet F, Lafont C, et al. Rapid sensing of circulating ghrelin by hypothalamic appetite-modifying neurons. Proc Nat Acad Sci USA 2013;110(4):1512-17
   PubMed Web of Science ®Google Scholar
• Amri: Obesity - mch-1 antagonists: AMRI Communications. 2011. Available from: http://www.amriglobal.com/news_and_publications/news_detail.cfm?ID=190
   Google Scholar
• Yeager CA, Winsberg B, Hobbs B. Weight-reducing effects of metformin are sustained over 40 weeks for psychiatric inpatients receiving polypharmacy. J Clin Psychopharmacol 2011;31(4):546-7
   PubMed Web of Science ®Google Scholar
• Krishna R, Gumbiner B, Stevens C, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 2009;86(6):659-66
   PubMed Web of Science ®Google Scholar
• RM-493: MC4R peptide therapeutic a new drug class for the treatment of obesity and diabetes. 2011. Available from: http://www.rhythmtx.com/PROGRAMS/RM493.html
   Google Scholar
• Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 2010;31(4):506-43
   PubMed Web of Science ®Google Scholar
• Wikberg JE, Mutulis F. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nat Rev 2008;7(4):307-23
   Google Scholar
• Larhammar D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 1996;65(3):165-74
   PubMed Web of Science ®Google Scholar
• Mashiko S, Moriya R, Ishihara A, et al. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis. Eur J Pharmacol 2009;615(1-3):113-17
   PubMed Web of Science ®Google Scholar
• Kanatani A, Mashiko S, Murai N, et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 2000;141(3):1011-16
   PubMed Web of Science ®Google Scholar
• Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006;4(4):275-82
   PubMed Web of Science ®Google Scholar
• Omori N, Kouyama N, Yukimasa A, et al. Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist. Bioorg Med Chem Lett 2012;22(5):2020-3
   PubMed Web of Science ®Google Scholar
• Siebenhofer A, Jeitler K, Berghold A, et al. Long-term effects of weight-reducing diets in hypertensive patients. Cochran Database Syst Rev 2011(9):CD008274
   Google Scholar
• Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000;404(6778):661-71
   PubMed Web of Science ®Google Scholar
• Sargent BJ, Moore NA. New central targets for the treatment of obesity. Br J Clin Pharmacol 2009;68(6):852-60
   PubMed Web of Science ®Google Scholar
• Wang GJ, Geliebter A, Volkow ND, et al. Enhanced striatal dopamine release during food stimulation in binge eating disorder. Obesity 2011;19(8):1601-8
   PubMed Web of Science ®Google Scholar
• Yoshimoto R, Miyamoto Y, Shimamura K, et al. Therapeutic potential of histamine h3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Nat Acad Sci USA 2006;103(37):13866-71
   PubMed Web of Science ®Google Scholar
• Masaki T, Chiba S, Yoshimichi G, et al. Neuronal histamine regulates food intake, adiposity, and uncoupling protein expression in agouti yellow (a(y)/a) obese mice. Endocrinology 2003;144(6):2741-8
   PubMed Web of Science ®Google Scholar
• Hancock AA, Bennani YL, Bush EN, et al. Antiobesity effects of A-331440, a novel non-imidazole histamine h3 receptor antagonist. Eur J Pharmacol 2004;487(1-3):183-97
   PubMed Web of Science ®Google Scholar
• A safety and efficacy study of HPP404 on weight loss in overweight or obese subjects. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01540864
   Google Scholar
• Passani MB, Blandina P, Torrealba F. The histamine h3 receptor and eating behavior. J Pharmacol Exp Ther 2011;336(1):24-9
   PubMed Web of Science ®Google Scholar
• Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9653):1906-13
   PubMed Web of Science ®Google Scholar
• Sjodin A, Gasteyger C, Nielsen AL, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes 2010;34(11):1634-43
   PubMed Web of Science ®Google Scholar
• Neurosearch reports on scientific advice received from the FDA and EMA concerning the clinical development programme for tesofensine. 2011. Available from: http://www.neurosearch.dk/Default.aspx?ID=16&M=News&PID=12&NewsID=16083
   Google Scholar
• Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009;17(1):30-9
   PubMed Web of Science ®Google Scholar
• Orexigen(r) therapeutics announces publication of cor-i phase 3 study of contrave in lancet. 2010. Available from: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1454172&highlight=
   Google Scholar
• Orexigen(r) therapeutics phase 2b trial for empatic(tm) meets primary efficacy endpoint demonstrating significantly greater weight loss versus comparators in obese patients. 2009. Available from: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1336796&highlight=
   Google Scholar
• Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372(6505):425-32
   PubMed Web of Science ®Google Scholar
• Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387(6636):903-8
   PubMed Web of Science ®Google Scholar
• Farooqi IS, O'Rahilly S. Monogenic obesity in humans. Annual review of medicine. 2005;56:443-58
   Google Scholar
• Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent progress in hormone research. 2004;59:287-304
   Google Scholar
• Schwartz MW, Baskin DG, Bukowski TR, et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996;45(4):531-5
   PubMed Web of Science ®Google Scholar
• Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995;377(6549):530-2
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Seeley RJ, Woods SC, et al. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 1997;46(12):2119-23
   PubMed Web of Science ®Google Scholar
• Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334(5):292-5
   PubMed Web of Science ®Google Scholar
• Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996;382(6588):250-2
   PubMed Web of Science ®Google Scholar
• Ozcan L, Ergin AS, Lu A, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 2009;9(1):35-51
   PubMed Web of Science ®Google Scholar
• Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Nat Acad Sci USA 2008;105(20):7257-62
   PubMed Web of Science ®Google Scholar
• Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009;17(9):1736-43
   PubMed Web of Science ®Google Scholar
• Amylin pharmaceuticals announces positive results from dose-ranging clinical study of pramlintide/metreleptin combination treatment for obesity. 2009. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1305954&highlight=metreleptin
   Google Scholar
• Pharmaceuticals A: Amylin and Takeda voluntarily suspend clinical activities in obesity trial. 2011
   Google Scholar
• Sayegh AI. The role of cholecystokinin receptors in the short-term control of food intake. Prog Mol Biol Transl Sci 2013;114:277-316
   PubMed Web of Science ®Google Scholar
• Moran TH. Cholecystokinin and satiety: current perspectives. Nutrition 2000;16(10):858-65
   PubMed Web of Science ®Google Scholar
• Moran TH, Baldessarini AR, Salorio CF, et al. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am J Physiol 1997;272(4 Pt 2):R1245-51
   PubMed Web of Science ®Google Scholar
• Moran TH, Shnayder L, Hostetler AM, McHugh PR. Pylorectomy reduces the satiety action of cholecystokinin. Am J Physiol 1988;255(6 Pt 2):R1059-63
   PubMed Web of Science ®Google Scholar
• Moran TH, Bi S. Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors. Philos Trans R Soc Lond B Biol Sci 2006;361(1471):1211-18
   PubMed Web of Science ®Google Scholar
• Beglinger C, Degen L, Matzinger D, et al. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol 2001;280(4):R1149-54
   PubMed Web of Science ®Google Scholar
• Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 1983;302(5910):703-6
   PubMed Web of Science ®Google Scholar
• Lukaszewski L, Praissman M. Effect of continuous infusions of CCK-8 on food intake and body and pancreatic weights in rats. Am J Physiol 1988;254(1 Pt 2):R17-22
   PubMed Web of Science ®Google Scholar
• West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 1984;246(5 Pt 2):R776-87
   PubMed Web of Science ®Google Scholar
• Fong TM. Advances in anti-obesity therapeutics. Expert Opin Investig Drugs 2005;14(3):243-50
   PubMed Web of Science ®Google Scholar
• Plusczyk T, Westermann S, Rathgeb D, Feifel G. Acute pancreatitis in rats: effects of sodium taurocholate, CCK-8, and sec on pancreatic microcirculation. Am J Physiol 1997;272(2 Pt 1):G310-20
   PubMed Web of Science ®Google Scholar
• Pandol SJ, Periskic S, Gukovsky I, et al. Ethanol diet increases the sensitivity of rats to pancreatitis induced by cholecystokinin octapeptide. Gastroenterology 1999;117(3):706-16
   PubMed Web of Science ®Google Scholar
• Matson CA, Ritter RC. Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight. Am J Physiol 1999;276(4 Pt 2):R1038-45
   PubMed Web of Science ®Google Scholar
• Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402(6762):656-60
   PubMed Web of Science ®Google Scholar
• Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003;23(22):7973-81
   PubMed Web of Science ®Google Scholar
• Carlini VP, Varas MM, Cragnolini AB, et al. Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. Biochem Biophys Res Commun 2004;313(3):635-41
   PubMed Web of Science ®Google Scholar
• Date Y, Murakami N, Toshinai K, et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002;123(4):1120-8
   PubMed Web of Science ®Google Scholar
• Naleid AM, Grace MK, Cummings DE, Levine AS. Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. Peptides 2005;26(11):2274-9
   PubMed Web of Science ®Google Scholar
• Beck B, Richy S. Dietary modulation of ghrelin and leptin and gorging behavior after weight loss in the obese Zucker rat. J Endocrinol 2009;202(1):29-34
   PubMed Web of Science ®Google Scholar
• Tschöp M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50(4):707-9
   PubMed Web of Science ®Google Scholar
• Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001;145(5):669-73
   PubMed Web of Science ®Google Scholar
• Tolle V, Kadem M, Bluet-Pajot MT, et al. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab 2003;88(1):109-16
   PubMed Web of Science ®Google Scholar
• Karra E, Yousseif A, Batterham RL. Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery. Trends Endocrinol Metabol 2010;21(6):337-44
   PubMed Web of Science ®Google Scholar
• Phase I/IIa clinical trial with obese individuals shows no effect of cyt009-ghrqb on weight loss. 2006. http://www.cytos.com/doc/Cytos_Press_E_061107.pdf
   Google Scholar
• Andrade M, Carreira M, Ribeiro A, et al. Development of an anti-ghrelin vaccine for obesity treatment 32 [abstract: P2-305]. The Endocrine Society's 93rd Annual Meeting & Expo. 4 – 7 June 2011; Boston, MA. Chevy Chase (MD): The Endocrine Society; 2011. p. 46
   Google Scholar
• Zorrilla EP, Iwasaki S, Moss JA, et al. Vaccination against weight gain. Proc Nat Acad Sci USA 2006;103(35):13226-31
   PubMed Web of Science ®Google Scholar
• Hornby PJ. Designing Spiegelmers to antagonise ghrelin. Gut 2006;55(6):754-5
   PubMed Web of Science ®Google Scholar
• Moran TH, Dailey MJ. Minireview: gut peptides: Targets for antiobesity drug development? Endocrinology 2009;150(6):2526-30
   PubMed Web of Science ®Google Scholar
• AEterna Zentaris products in development: AEZS-123 ghrelin receptor antagonist. 2011. Available from: http://www.aezsinc.com/en/page.php?p=32&prod=28
   Google Scholar
• Yang J, Zhao TJ, Goldstein JL, Brown MS. Inhibition of ghrelin o-acyltransferase (goat) by octanoylated pentapeptides. Proc Nat Acad Sci USA 2008;105:31:10750-5
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3(3):153-65
   PubMed Web of Science ®Google Scholar
• Meeran K, O'Shea D, Edwards CM, et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999;140(1):244-50
   PubMed Web of Science ®Google Scholar
• Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379(6560):69-72
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101(3):515-20
   PubMed Web of Science ®Google Scholar
• Naslund E, King N, Mansten S, et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 2004;91(3):439-46
   PubMed Web of Science ®Google Scholar
• Michel MC, Fliers E, Van Noorden CJ. Dipeptidyl peptidase iv inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism? Naunyn Schmiedebergs Arch Pharmacol 2008;377(3):205-7
   PubMed Web of Science ®Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298(2):194-206
   PubMed Web of Science ®Google Scholar
• Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86(1):44-57
   PubMed Web of Science ®Google Scholar
• Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303(14):1410-18
   PubMed Web of Science ®Google Scholar
• Pratley RE. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med 2008;10(7):171
   PubMedGoogle Scholar
• Oral GLP-1, for type 2 diabetes. 2011. Available from: http://www.emisphere.com/oral_GLP-1.html
   Google Scholar
• Steinert RE, Poller B, Castelli MC, et al. Oral administration of glucagon-like peptide 1 or peptide YY3-36 affects food intake in healthy male subjects. Am J Clin Nutr 2010;92(4):810-17
   PubMed Web of Science ®Google Scholar
• Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349(10):941-8
   PubMed Web of Science ®Google Scholar
• Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes 2006;30(12):1729-36
   PubMed Web of Science ®Google Scholar
• Prolor Biotech reports positive preclinical results in weight loss study of its long-acting anti-obesity drug candidate. 2011. Available from: http://www.theglobeandmail.com/globe-investor/news-sources/?date=20110606&archive=prnews&slug=NY14327
   Google Scholar
• Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985;89(5):1070-7
   PubMed Web of Science ®Google Scholar
• Liu CD, Aloia T, Adrian TE, et al. Peptide YY: a potential proabsorptive hormone for the treatment of malabsorptive disorders. Am Surg 1996;62(3):232-6
   PubMed Web of Science ®Google Scholar
• le Roux CW, Batterham RL, Aylwin SJ, et al. attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006;147(1):3-8
   PubMed Web of Science ®Google Scholar
• Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418(6898):650-4
   PubMed Web of Science ®Google Scholar
• Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005;129(5):1430-6
   PubMed Web of Science ®Google Scholar
• Ortiz AA, Milardo LF, DeCarr LB, et al. A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents. J Pharmacol Exp Ther 2007;323(2):692-700
   PubMed Web of Science ®Google Scholar
• Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007;92(5):1754-7
   PubMed Web of Science ®Google Scholar
• Pittner RA, Albrandt K, Beaumont K, et al. Molecular physiology of amylin. J Cell Bioch 1994;55(Suppl):19-28
   PubMedGoogle Scholar
• Koda JE, Fineman M, Rink TJ, et al. Amylin concentrations and glucose control. Lancet 1992;339(8802):1179-80
   PubMed Web of Science ®Google Scholar
• Edwards GL GB, Jodka C, Dilts RP, et al. Area postrema (AP) - lesions block the regulation of gastric emptying by amylin. Neurogastroenterol Motil 1998;10(4):26
   Google Scholar
• Lutz TA, Mollet A, Rushing PA, et al. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord 2001;25(7):1005-11
   PubMed Web of Science ®Google Scholar
• Rushing PA, Hagan MM, Seeley RJ, et al. Amylin: a novel action in the brain to reduce body weight. Endocrinology 2000;141(2):850-3
   PubMed Web of Science ®Google Scholar
• Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther 2002;4(2):175-89
   PubMedGoogle Scholar
• Young AVW, Gedulin BR, et al. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev Res 1996;37(4):231-48
   Web of Science ®Google Scholar
• Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003;26(3):784-90
   PubMed Web of Science ®Google Scholar
• Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002;4(1):51-61
   PubMedGoogle Scholar
• Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25(4):724-30
   PubMed Web of Science ®Google Scholar
• Maggs D, Shen L, Strobel S, et al. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism 2003;52(12):1638-42
   PubMed Web of Science ®Google Scholar
• Hort Y, Baker E, Sutherland GR, et al. Gene duplication of the human peptide YY gene (PYY) generated the pancreatic polypeptide gene (PPY) on chromosome 17q21.1. Genomics 1995;26(1):77-83
   PubMed Web of Science ®Google Scholar
• Adrian TE, Bloom SR, Bryant MG, et al. Distribution and release of human pancreatic polypeptide. Gut 1976;17(12):940-4
   PubMed Web of Science ®Google Scholar
• Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci 2006;361(1471):1187-209
   PubMed Web of Science ®Google Scholar
• Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003;124(5):1325-36
   PubMed Web of Science ®Google Scholar
• Malaisse-Lagae F, Carpentier JL, Patel YC, et al. Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. Hypothesis. Experientia 1977;33(7):915-17
   PubMedGoogle Scholar
• Reinehr T, Enriori PJ, Harz K, et al. Pancreatic polypeptide in obese children before and after weight loss. Int J Obes 2006;30(10):1476-81
   Web of Science ®Google Scholar
• Fujimoto S, Inui A, Kiyota N, et al. Increased cholecystokinin and pancreatic polypeptide responses to a fat-rich meal in patients with restrictive but not bulimic anorexia nervosa. Biol Psychiatry 1997;41(10):1068-70
   PubMed Web of Science ®Google Scholar
• Batterham RL, Le Roux CW, Cohen MA, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003;88(8):3989-92
   PubMed Web of Science ®Google Scholar
• Adrian TE, Greenberg GR, Besterman HS, Bloom SR. Pharmacokinetics of pancreatic polypeptide in man. Gut 1978;19(10):907-9
   PubMed Web of Science ®Google Scholar
• 7tm-pharma: Obinepitide. 2011. http://www.7tm.com/R-D/Metabolic_Disorders/Obinepitide.aspx
   Google Scholar
• 7TM Pharma: TM30339. 2011. Avaialble from http://www.7tm.com/R-D/Metabolic_Disorders/TM30339.aspx
   Google Scholar
• Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294(5549):2166-70
   PubMed Web of Science ®Google Scholar
• Smith SJ, Cases S, Jensen DR, et al. obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT. Nat Genet 2000;25(1):87-90
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yamaguchi H, Miki H, et al. A novel coenzyme a: diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity. Eur J Pharmacol 2011;650(2-3):663-72
   PubMed Web of Science ®Google Scholar
• Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes 2007;31(3):494-9
   Web of Science ®Google Scholar
• Datta B. Roles of p67/metap2 as a tumor suppressor. Biochim Biophys Acta Rev Cancer 2009;1796(2):281-92
   PubMed Web of Science ®Google Scholar
• Lijnen HR, Frederix L, Van Hoef B. Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity. Obesity 2010;18(12):2241-6
   PubMed Web of Science ®Google Scholar
• Zafgen announces positive topline phase 1b data for zgn-433 in obesity. 2011. Available from: http://www.zafgen.com/news.html
   Google Scholar
• Ross R. The challenge of obesity treatment: avoiding weight regain. CMAJ 2009;180(10):997-8
   PubMed Web of Science ®Google Scholar
• Sarwer DB, von Sydow Green A, Vetter ML, Wadden TA. Behavior therapy for obesity: where are we now? Curr Opin Endocrinol Diabetes obesity 2009;16(5):347-52
   PubMed Web of Science ®Google Scholar
• Kraschnewski JL, Boan J, Esposito J, et al. Long-term weight loss maintenance in the united states. Int J Obes 2010;34(11):1644-54
   PubMed Web of Science ®Google Scholar
• Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. National Institutes of Health. 1998. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9813653
   Google Scholar
• Cao DX, Wu GH, Zhang B, et al. Resting energy expenditure and body composition in patients with newly detected cancer. Clin Nutr 2010;29(1):72-7
   PubMed Web of Science ®Google Scholar
• Plasqui G, Westerterp KR. Seasonal variation in total energy expenditure and physical activity in Dutch young adults. Obes Res 2004;12(4):688-94
   PubMedGoogle Scholar
• Weigle DS. Appetite and the regulation of body composition. FASEB J 1994;8(3):302-10
   PubMed Web of Science ®Google Scholar
• Bray GA, Smith SR, DeJonge L, et al. Effect of diet composition on energy expenditure during weight loss: the pounds lost study. Int J Obes 2012;36(3):448-55
   Web of Science ®Google Scholar
• Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995;332(10):621-8
   PubMed Web of Science ®Google Scholar
• Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011;365(17):1597-604
   PubMed Web of Science ®Google Scholar
• Adam TC, Jocken J, Westerterp-Plantenga MS. Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects. Obes Res 2005;13(4):710-16
   PubMedGoogle Scholar
• Essah PA, Levy JR, Sistrun SN, et al. Effect of weight loss by a low-fat diet and a low-carbohydrate diet on peptide YY levels. Int J Obes 2010;34(8):1239-42
   Web of Science ®Google Scholar
• De Silva A, Salem V, Long CJ, et al. The gut hormones PYY3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 2011;14(5):700-6
   PubMed Web of Science ®Google Scholar
• Neary NM, Small CJ, Druce MR, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005;146(12):5120-7
   PubMed Web of Science ®Google Scholar
• Field BC, Wren AM, Peters V, et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010;59(7):1635-9
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Degen L, Matzinger D, et al. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am J Physiol Regul Integr Comp Physiol 2004;287(3):R562-7
   PubMed Web of Science ®Google Scholar
• Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000;52(3):375-414
   PubMed Web of Science ®Google Scholar
• Ramani GV, Park MH. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. Drug Des Dev Ther 2010;4:61-70
   PubMed Web of Science ®Google Scholar
• Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010;62(3):525-63
   PubMed Web of Science ®Google Scholar
• Degerman E, Ahmad F, Chung YW, et al. From pde3b to the regulation of energy homeostasis. Curr Opin Pharmacol 2011;11(6):676-82
   PubMed Web of Science ®Google Scholar
• Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell 1990;63(5):941-8
   PubMed Web of Science ®Google Scholar
• Potter LR. Guanylyl cyclase structure, function and regulation. Cell Signal 2011;23(12):1921-6
   PubMed Web of Science ®Google Scholar
• Lin JE, Li P, Pitari GM, et al. Guanylyl cyclase c in colorectal cancer: susceptibility gene and potential therapeutic target. Future Oncol 2009;5(4):509-22
   PubMed Web of Science ®Google Scholar
• Lin JE, Snook AE, Li P, et al. Gucy2c opposes systemic genotoxic tumorigenesis by regulating akt-dependent intestinal barrier integrity. PLoS One 2012;7(2):e31686
   PubMed Web of Science ®Google Scholar
• Valentino MA, Lin JE, Snook AE, et al. A uroguanylin-gucy2c endocrine axis regulates feeding in mice. J Clin Invest 2011;121(9):3578-88
   PubMed Web of Science ®Google Scholar
• Ray K. IBS: linaclotide approved for constipation-predominant IBS. Nat Rev Gastroenterol Hepatol 2012
   Google Scholar
• McWilliams V, Whiteside G, McKeage K. Linaclotide: first global approval. Drugs 2012;72(16):2167-75
   PubMed Web of Science ®Google Scholar
• Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009;360(15):1509-17
   PubMed Web of Science ®Google Scholar
• Bordicchia M, Liu D, Amri EZ, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 2012;122(3):1022-36
   PubMed Web of Science ®Google Scholar
• Miyashita K, Itoh H, Tsujimoto H, et al. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 2009;58(12):2880-92
   PubMed Web of Science ®Google Scholar
• Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003;299(5608):896-9
   PubMed Web of Science ®Google Scholar
• Jennissen K, Haas B, Kunz W, Pfeifer A. cGMP and cAMP differentially regulate differentiation and function of brown adipocytes. BMC Pharmacol 2011;11(Suppl 1):P37
   Google Scholar
• Mitschke MM, Hoffmann LS, Gnad T, et al. Increased cGMP promotes healthy expansion and browning of white adipose tissue. FASEB J 2013
   PubMed Web of Science ®Google Scholar